Fresenius Medical target raised to $55 from $50 at RBC Capital
RBC believes Fresenius Medical reported solid Q3 results as its quality metrics continue to improve. The firm raised its target on shares and maintains an Outperform rating. :theflyonthewall.com
News For FMS From The Last 14 Days
Check below for free stories on FMS the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
